Investegate |Global Blood Therapeutics, Inc Announcements | Global Blood Therapeutics, Inc: GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Investegate announcements from Global Blood Therapeutics, Inc, GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease